论文部分内容阅读
目的:分析研究艾滋病(HIV)合并结核病(TB)的双重感染患者的耐多药现状,为此种疾病的宣传防治工作、临床治疗工作提供正确的理论基础及指导方向。方法:以已确诊为结核病(TB)合并艾滋病(HIV)双重感染的患者40例为观察组,以我院同时期收治的结核病(TB)患者154例为对照组,通过对两组患者的结核杆菌的菌种鉴定和对异烟肼(INF,H)、利福平(RFP,R)、乙胺丁醇(EMB,E)、链霉素(SM,S)、对氨基水杨酸钠(PAS,P)等抗结核药物的耐药检测,分析比较两组结核杆菌的初始耐多药率、获得性耐多药率及总耐多药率。结果:艾滋病合并结核感染的患者在初始耐药率(39.39%)和初始耐多药率(18.18%)明显高于只感染结核的对照组(9.35%、3.74%),差异有统计学意义(P<0.05)。结论:结核病艾滋病双重感染的患者耐药性和耐多药性高,治疗困难,复发率和死亡率高。因此,加强艾滋病防治宣传教育是十分必要的。同时,相关部门也应该更加重视结核病、艾滋病的防治工作,保护公众的健康。
Objective: To analyze the status of multidrug resistance (MDR) in patients with dual infection of HIV / AIDS and tuberculosis (TB) and provide the correct theoretical basis and direction for the publicity and prevention of this disease and clinical treatment. Methods: A total of 40 TB patients with tuberculosis (TB) complicated with HIV infection who were diagnosed as TB were selected as the observation group and 154 TB patients treated by the same period as the control group. The identification of bacilli and the identification of isoniazid (INF, H), rifampicin (RFP, R), ethambutol (EMB, E), streptomycin (SM, S) (PAS, P) and other anti-tuberculosis drug resistance testing, analysis and comparison of the two groups of Mycobacterium tuberculosis initial multi-drug resistance rate, acquired multidrug resistance rate and multidrug resistance rate. Results: The initial drug resistance rate (39.39%) and initial multidrug resistance rate (18.18%) in patients with AIDS complicated with tuberculosis infection were significantly higher than those in the control group (9.35%, 3.74%) infected with tuberculosis only, with significant difference P <0.05). Conclusions: Patients with dual infection of HIV / AIDS and tuberculosis have high drug resistance and multi-drug resistance, difficult to treat, high relapse rate and high mortality rate. Therefore, it is very necessary to strengthen the publicity and education on AIDS prevention and control. At the same time, the relevant departments should also pay more attention to tuberculosis and AIDS prevention and control work to protect the public’s health.